Medication info
Citrica Capsule 150 mg (Pregabalin)

Citrica Capsule 150 mg (Pregabalin)

Prescription medicationHard capsule
Ingredient · strength
Pregabalin›150mg / 1 capsule
Manufacturer / importer
HLB Pharmaceuticals Co., Ltd.
Appearance
A hard capsule with a white upper part and a white lower part containing a powder that is white to light yellow in color
Packaging
30 capsules/bottle
Approval status
Active

MFDS item code 201902047 · Approved 2019.04.04 · Insurance code 647303750

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures
Who uses it
Adults · Children
Adult dosage
This medicine is administered orally, with or without food, in 2 divided doses per day, for a total daily dose of pregabalin. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. After an additional week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’.) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, it may be increased within 1 week to 225 mg twice daily (450 mg/day). Although clinical studies were also conducted at a dose of 600 mg/day, there is no evidence of additional benefit or adequate tolerability at this dose. Considering dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with renal impairment Dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose determined according to renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. ≥60 mL/min: Starting dose 150 mg/day, maximum dose 600 mg/day, BID or TID ≥30 -<60 mL/min: Starting dose 75 mg/day, maximum dose 300 mg/day, BID or TID ≥15 -<30 mL/min: Starting dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID <15 mL/min: Starting dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: 25 mg, maximum dose 100 mg, single dose TID = Total daily dose administered in 3 divided doses BID = Total daily dose administered in 2 divided doses QD = Administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified under the method of administration. b: Supplemental dose refers to a dose administered once in addition to the regular dose. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older adults (65 years or older) Dose reduction may be necessary in older adults with impaired renal function.
Children's dosage
Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12 ~17 years: Administration is not recommended because there are insufficient data on safety and efficacy.

Ingredients

Manufacturer
HLB Pharmaceuticals Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia
View approved original text

This medication is used to effectively treat peripheral and central neuropathic pain in adults. It is also used as an adjunctive therapy alongside primary medication for patients with epilepsy who exhibit partial seizures. Additionally, it is helpful in alleviating pain for patients with fibromyalgia. Overall, it is effective for neuropathic pain and seizure disorders, contributing to the improvement of symptoms in patients.

Dosage and Administration

Adult dosage

This medicine is administered orally, with or without food, in 2 divided doses per day, for a total daily dose of pregabalin. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. After an additional week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’.) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, it may be increased within 1 week to 225 mg twice daily (450 mg/day). Although clinical studies were also conducted at a dose of 600 mg/day, there is no evidence of additional benefit or adequate tolerability at this dose. Considering dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with renal impairment Dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose determined according to renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. ≥60 mL/min: Starting dose 150 mg/day, maximum dose 600 mg/day, BID or TID ≥30 -<60 mL/min: Starting dose 75 mg/day, maximum dose 300 mg/day, BID or TID ≥15 -<30 mL/min: Starting dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID <15 mL/min: Starting dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: 25 mg, maximum dose 100 mg, single dose TID = Total daily dose administered in 3 divided doses BID = Total daily dose administered in 2 divided doses QD = Administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified under the method of administration. b: Supplemental dose refers to a dose administered once in addition to the regular dose. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older adults (65 years or older) Dose reduction may be necessary in older adults with impaired renal function.

Children's dosage

Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12 ~17 years: Administration is not recommended because there are insufficient data on safety and efficacy.

Precautions

This medication may increase the risk of suicidal thoughts or actions, so mood changes or symptoms of depression should be carefully monitored during treatment. Patients with hypersensitivity to this medication or specific genetic issues such as lactose intolerance should not use it. Diabetic patients should be cautious as weight gain may require adjustments in glycemic control medications. If symptoms of angioedema occur, this medication should be discontinued immediately. Elderly patients experiencing severe dizziness or drowsiness may be at risk of falls and should take caution. Blurred vision or changes in vision may improve upon discontinuation of this medication. Abrupt withdrawal may lead to withdrawal symptoms such as insomnia, headache, and anxiety, so it should be tapered off gradually in consultation with a healthcare professional. Patients with a history of drug abuse should take special care due to the risk of abuse associated with this medication. Dose adjustments may be necessary for patients with impaired renal function. Patients with heart disease should exercise caution while taking this medication, and concurrent use with opioid analgesics increases the risk of central nervous system depression. Patients with compromised respiratory function or the elderly may be at risk of severe respiratory depression, making dose adjustments necessary. Pregnant women should avoid this medication during early pregnancy due to the potential risk of fetal malformation, and women of childbearing age should use effective contraception. Breastfeeding women should consider stopping breastfeeding or discontinuing this medication, as it can be passed into breast milk. Dizziness or drowsiness may occur when driving or operating machinery, necessitating caution until symptoms have completely resolved. Severe skin reactions can occur, so if symptoms such as skin rash or swelling arise, the medication should be discontinued immediately and medical advice sought. Overdose may result in mental confusion, drowsiness, depression, and seizures, requiring immediate medical attention, and blood dialysis may be necessary if required. This medication may require dose adjustments for special populations such as children or the elderly, and it should be taken as directed by a healthcare professional. This medication has minimal drug interactions, but the risk of side effects increases when taken with central nervous system depressants, so it is imperative to inform healthcare professionals of all medications being taken.

Side effects

  • Suicidal thoughts
  • suicidal behavior
  • depression
  • abnormal changes in mood and behavior
  • angioedema
  • facial swelling
  • swelling around the mouth
  • upper respiratory tract swelling
  • dizziness
  • drowsiness
Show 183 more
  • loss of consciousness
  • confusion
  • mental disorders
  • blurred vision
  • vision changes
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like illness
  • restlessness
  • depression
  • suicidal ideation
  • pain
  • seizures
  • hyperhidrosis
  • misuse
  • abuse
  • dependence
  • weight gain
  • rhinosinusitis
  • neutropenia
  • increased appetite
  • decreased appetite
  • hypoglycemia
  • confusion
  • disorientation
  • irritability
  • euphoria
  • decreased libido
  • depersonalization
  • paraphilia
  • agitation
  • mood swings
  • emotional reduction
  • emotional elevation
  • difficulty in finding appropriate terms
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • inability to inhibit
  • emotional flatness
  • ataxia
  • motor coordination abnormalities
  • balance disorders
  • amnesia
  • attention disorders
  • memory disorders
  • tremors
  • speech impairment
  • sensory disturbances
  • sensory reduction
  • sedation
  • somnolence
  • cognitive impairment
  • nystagmus
  • language disorders
  • myoclonic jerks
  • reduced reflexes
  • movement disorders
  • psychomotor agitation
  • positional dizziness
  • perception hypersensitivity
  • burning sensation
  • activity tremors
  • syncope
  • delirium
  • psychomotor retardation
  • olfactory disturbances
  • loss of taste
  • writing impairment
  • diplopia
  • vertigo
  • auditory hypersensitivity
  • first-degree AV block
  • tachycardia
  • homonymous bradycardia
  • homonymous tachycardia
  • homonymous arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • throat tension
  • nasal dryness
  • respiratory depression
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • flatulence
  • excessive salivation
  • gastroesophageal reflux disease
  • oral sensory reduction
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweat
  • muscle cramps
  • joint pain
  • back pain
  • limb pain
  • uterine contractions
  • joint swelling
  • myalgia
  • muscle spasms
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urination disorders
  • urinary incontinence
  • decreased urination
  • kidney failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • mastalgia
  • nipple discharge
  • gynecomastia
  • peripheral edema
  • edema
  • walking abnormalities
  • falls
  • feeling drunk
  • sensory abnormalities
  • fatigue
  • tightness in the chest
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood sugar
  • decreased platelet count
  • decreased serum potassium
  • increased serum creatinine
  • decreased white blood cell count
  • hypersensitivity
  • allergic reactions
  • headache
  • keratitis
  • congestive heart failure
  • pulmonary edema
  • nausea
  • diarrhea
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • lethargy
  • delirium
  • paralysis (facial paralysis)
  • affective disorders
  • drowsiness
  • confusion
  • agitation
  • restlessness
  • seizures
  • shock
  • anaphylaxis-like symptoms
  • skin and mucous membrane syndrome
  • erythema multiforme

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly sealed container to protect it from air and moisture. It is important to maintain the storage temperature between 15 to 30 degrees Celsius.

Appearance and packaging

Appearance

A hard capsule with a white upper part and a white lower part containing a powder that is white to light yellow in color

Package unit

30 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.